Clinical Trials Logo

Clinical Trial Summary

The objectives of this study are to evaluate the EV71vaccine efficacy, immune response and safety profiles after two injections of the cell culture-based inactivated EV71 vaccine with adjuvant Al(OH)3 administrated in pediatric population aged 2 months to 6 years old.


Clinical Trial Description

The clinical trial designed in this Study is a placebo-controlled, double-blinded Phase III and is aimed to evaluate the vaccine efficacy, safety, immunogenicity and immune persistence of cell culture-based inactivated EV71 vaccine in children age of 2 months to <6 years old. Two doses of Alum-adjuvanted 1.0 μg per dose of EV71 vaccine candidate will be administrated to subjects. The efficacy will be evaluated within a two year period after receiving 2-regimen vaccination by comparing the EV71-associated disease rates between the vaccine and placebo groups. Whereas, the immunogenicity will be assessed on Day 56 and Day 196, and the immune persistence will be evaluated on Day 392. Safety will be followed up to Day 392. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05099029
Study type Interventional
Source Enimmune Corporation
Contact
Status Enrolling by invitation
Phase Phase 3
Start date June 27, 2018
Completion date December 31, 2024

See also
  Status Clinical Trial Phase
Completed NCT04091880 - Evaluation of the Safety and Immunogenicity of Simultaneously Administration of EV71 Vaccine and Influenza Vaccine Phase 4
Recruiting NCT06149494 - RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection Phase 2
Completed NCT01313715 - A Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants Phase 1
Completed NCT00426699 - Urinary Excretion of Enteroviruses From Children With a Presumed Enteroviral Infection N/A
Recruiting NCT06263439 - Surveillance of HFMD in Pediatric Outpatients
Completed NCT05016687 - First-in-human Clinical Trial Evaluating CUR-N399 in Healthy Volunteers. Phase 1
Completed NCT03268083 - A Study to Evaluate the Immunogenicity and Safety of EV71 Vaccine in Pediatric Subjects Phase 2
Terminated NCT01129232 - Diabetes Virus Detection Project, Intervention With GAD-alum Phase 2
Recruiting NCT04431050 - Evaluation of a Single Use Point of Care Device for the Diagnosis of Respiratory Pathogens
Active, not recruiting NCT04769167 - Congenital Heart Anomaly Risk in Maternal Enteroviral Infection and Diabetes N/A
Completed NCT02777411 - A Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 6 to 35 Months Old Phase 2
Withdrawn NCT04535648 - Detection of Enterovirus Genotypes by CRISPR Technology